Member Info for undervaluedtoday

37p per share, once wider commercial adoption by pharmaceutical groups

Broad Market Consensus

According to tracking data across aggregate platforms like London Stock Exchange ShareChat and ADVFN, analyst sentiment sits at a Strong Buy:

Conservative Average Target: 4.0p to 7.0p.

High-End Speculative Estimates: Up to 30.0p.

Valuation Forecast: Independent estimates (such as Trinity Delta) model the fundamental underlying value of the technology portfolio at up to £118 million, or roughly 37p per share, once wider commercial adoption by pharmaceutical groups is achieved.

2P+ GOING into close buyers expecting news and so am i

5p will bring a rush of buyers watch

Holding rns due

I thought posting live data was against forum rules anyway your lying

Buy price moving up with every buy tells its own story

Yes noticed the haters do not like anything positive why is that guys

Do not blink when this starts moving plenty will rush in as they fence sitting

Volume buying deffo increasing

Market Activity: The connection has sparked significant discussion among Nuformix (LON:NFX) shareholders and investors regarding potential joint technology synergies or future funding support.

Next week by any chance

3rd Resistance Point 2.097

2nd Resistance Point 1.999

1st Resistance Point 1.899

Last Price 1.900

https://www.adventhealth.com/institutes/research/news/advancing-cancer-research-closer-home

See you back when we are multiples 10-15-20-25p+

Crazy low imho double digits next RNS

Moving up now about time

And still loading

💯☝️

Strange

NO brainer

🤡😆😚